Since aldosterone is known to promote interstitial fibrosis in cardiac tissues, it is possible that aldosterone may influence cardiac structure and function. In the present study, we investigated whether plasma aldos- 
Introduction
Left ventricular (LV) hypertrophy, the most common cardiac consequence of hypertension, is considered as a maladaptation to the increased afterload, because it is one of the independent risk factors for cardiovascular complications and death (1, 2) . However, the hemodynamic load is not the only determinant of LV hypertrophy, because for similar elevations of blood pressure, a wide range of severities and types powerful stimulator of myocyte growth, and many studies have shown the relation of plasma angiotensin II to LV hypertrophy in essential hypertension (9 -11) . These findings suggest that a blockade of angiotensin II production by use of angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers has beneficial effects against the progression of LV hypertrophy in hypertensive patients. However, the role of aldosterone escape during long-term treatment with these drugs in heart failure and hypertension has recently attracted a great deal of attention (12, 13) , and some studies have suggested that aldosterone escape may reverse the beneficial effects of an ACE inhibitor on LV hypertrophy (13, 14) . Therefore, it is possible that plasma aldosterone may add some modification to the alteration of LV structure in chronically treated hypertensive patients.
Myocardial hypertrophy also involves increases in extracellular matrix and collagen deposition and variable extents of fibrosis (15, 16) . Such interstitial fibrosis in cardiac tissues can influence not only LV geometry but also LV diastolic function. Since aldosterone is known to induce interstitial fibrosis rather than cardiomyocyte hypertrophy (15, 17, 18) , this substance may affect LV diastolic function. Thus, it is important to evaluate the involvement of aldosterone in the impairment of LV diastolic function in hypertensive subjects, since both LV diastolic dysfunction (abnormal relaxation) and LV hypertrophy are common cardiac changes in these subjects. Nevertheless, little is known about the relationship between plasma aldosterone and LV diastolic function in essential hypertension.
Therefore, the major aim of the present study was to clarify the relations of circulating aldosterone levels to LV geometry and diastolic function in patients with treated essential hypertension.
Methods

Patients
A total of 92 patients with essential hypertension (42 males and 50 females; mean age, 59 years) were selected among hypertensive patients admitted to our hospital. Patients with secondary hypertension, ischemic heart disease including cases of myocardial infarction, valvular heart disease, atrial fibrillation, congestive heart failure, renal failure, or unsatisfactory B-mode and Doppler echocardiograms were excluded from the study. Hypertension was defined as a systolic blood pressure of ≥140 mmHg and/or a diastolic blood pressure of ≥90 mmHg by repeated measurements or as the taking of medication for treatment of hypertension. Of the 92 patients, 70 (76%) were receiving antihypertensive drugs, including combination therapy. Sixty-one patients (66%) were treated with calcium channel blockers, 31 (34%) with ACE inhibitors, 28 (30%) with β-blockers, 11 (12%) with diuretics, and 10 (11%) with other classes of agents. Twenty-two patients (24%) were treated with diet and/or exercise therapy (without antihypertensive medication). All subjects gave informed consent to participate in the present study.
Measurement of Plasma Aldosterone Concentration (PAC)
Blood samples were taken early in the morning on the day of echocardiographic examination from the brachial vein after a resting period of at least 30 min in the supine position. The measurement of PAC was performed using a radioimmunoassay method as previously reported (19) . Serum creatinine, serum potassium, and plasma renin activity were also measured.
Echocardiographic Measurement
Comprehensive two-dimensional echocardiography was performed with a cardiac ultrasound unit (Sonos 5500; Hewlett Packard, Andover, USA) as previously described (20) . Measurements included left atrial end systolic dimension, interventricular septal thickness (IVSTd), posterior wall thickness (PWTd), LV diameter at end-diastole (LVDd), and LV diameter at end-systole (LVDs). Fractional shortening was calculated as (LVDd LVDs)/LVDd. LV relative wall thickness (RWT) was calculated as (IVSTd PWTd)/LVDd. LV mass was estimated using the formula validated by Devereux and Reichek (21) The geometry of LV was stratified into four different patterns according to the values of LVMI and RWT (2, 3) . Upper normal limits for LVMI were 134 and 110 g/m 2 in men and women, respectively (22, 23) . A partition value of 0.45 for RWT was used for both men and women (4, 23) . Patients with increased LVMI and increased RWT were considered to have concentric hypertrophy, and those with increased LVMI and normal RWT were considered to have eccentric hypertrophy. Those with normal LVMI and increased or normal RWT were considered to have concentric remodeling or normal geometry, respectively (3).
To assess LV diastolic function, the diastolic filling of LV (LV inflow) was examined using Doppler echocardiography. The LV diastolic filling pattern was obtained with the sample volume at the tips of the mitral valve in the apical fourchamber view and recorded at the end-expiratory phase during quiet breathing (24) . The peak velocity of the early diastolic filling wave (E wave) and the peak velocity of atrial filling (A wave) were recorded and the E to A ratio (E/A) was calculated. The deceleration time was measured as the time between the top of the E wave and the point where the descending part of the E wave or its asymptote crossed the zero line. LV isovolumic relaxation time was measured as the time between the aortic closure click and the start of the E wave.
Statistical Analysis
Values are expressed as the means SE. Relations between variables were assessed using univariate linear regression analyses and Pearson's correlation coefficient. Multiple regression analyses were also performed to identify possible determinants of LV diastolic function. An unpaired Student's t-test was used for comparison between the two groups. The significance of differences among more than three groups was evaluated by one-way analysis of variance with subsequent Fisher's multiple comparison test. Levels of p 0.05 were considered to indicate statistical significance. Table 1 shows the patient characteristics and antihypertensive drug treatments for each of the four LV geometric patterns. Of the 92 patients in the present study, 17 displayed normal LV geometry, 26 displayed concentric remodeling, 20 displayed eccentric hypertrophy, and 29 displayed concentric hypertrophy. The percentage of male gender was higher, and body mass index and systolic blood pressure were somewhat increased in patients with concentric hypertrophy compared with the other groups. There were no significant differences in renal function, serum potassium level, or plasma renin activity among the four groups. The percentage of subjects treated with an ACE inhibitor was higher in patients with concentric hypertrophy (41%) and with eccentric hypertrophy (50%) than in those with normal geometry (12%).
Results
Association of LV Geometry with LV Diastolic Function
The correlation between LV diastolic function and LV hypertrophy was examined in the overall subject group. The E/A ratio, an index of LV diastolic function, was negatively correlated with IVSTd (r 0.27, p 0.009) and RWT (r 0.24, p 0.02), although it had no direct correlation with LVMI (r 0.09, p 0.39). After adjustment for age, sex, body mass index, and systolic blood pressure, RWT was still correlated with the E/A ratio (p 0.04).
To evaluate the effect of LV geometric patterns on LV diastolic function, each parameter of LV inflow was compared among the four groups with different LV geometries. Although the E wave showed no change among the four groups, the A wave was higher in patients with concentric hypertrophy than in those with normal geometry ( Table 2) . The E/A ratio in subjects with concentric hypertrophy was significantly lower than in those with normal geometry (Fig.  1 ). There were no significant differences in the deceleration time of the E wave or isovolumic relaxation time among the four groups, but both parameters were longest in patients with concentric hypertrophy.
Association of Plasma Aldosterone with LV Geometry
To examine whether antihypertensive treatment affected aldosterone levels, we compared PAC between subjects with and without treatment by each antihypertensive drug. However, there was no difference in PAC between the two groups under treatment with any antihypertensive drug (Table 3) . In linear regression analyses, no significant correlation was detected between PAC and any echocardiographic parameter of LV hypertrophy, i.e., IVSTd, PWTd, LVDd, RWT, or LVMI (data not shown). When patients were divided into four groups by LV geometric patterns, however, PAC was associated with specific patterns of LV geometry (Fig. 2) . The highest value was present in eccentric LV hypertrophy. PAC in patients with eccentric hypertrophy was significantly higher than in those with concentric hypertrophy (15.2 2.1 vs. 10.0 0.7 ng/dl, p 0.008).
Association of Plasma Aldosterone with LV Diastolic Function
We next investigated the relation of aldosterone with Doppler parameters of diastolic filling. In a univariate linear regression, no simple association was detected between PAC In a multiple regression analysis, however, not only age (p 0.001), heart rate (p 0.005), and RWT (p 0.01), but also PAC (p 0.04) was an independent determinant of the E/A ratio (Table 4) . Since the present findings suggested that the concentric change in LV geometry strongly influenced LV relaxation abnormalities, removal of the effect of the concentric LV geometric alteration on LV diastolic function was needed to clarify the association of plasma aldosterone with LV diastolic function in hypertensive patients. Thus, in the subgroup with normal RWT (i.e., without the concentric change in LV geometry), the association of plasma aldosterone with LV diastolic function was examined. In the subgroup with increased RWT (i.e., with the concentric change in LV geometry), PAC showed no significant correlation with the E/A ratio (Fig. 3) . In the subgroup with normal RWT, however, PAC was negatively correlated with E/A (r 0.35, p 0.03). Furthermore, compared with patients with lower PAC ( 13 ng/dl), those with higher PAC (≥13 ng/dl) had a significantly lower E/A ratio in the subgroup with normal RWT (Fig. 4) , whereas such a difference by the level of PAC was not observed in the subgroup with increased RWT.
Discussion
The present study has demonstrated in patients with treated essential hypertension that plasma aldosterone is associated with the eccentric change in LV geometry rather than with LV hypertrophy. Our study has also shown that the elevation of aldosterone levels is related, in part, to the impairment of LV diastolic function. To our knowledge, this is the first study to report that circulating aldosterone has significant associations both with LV structural change and with LV diastolic dysfunction in treated essential hypertension.
Many studies have shown that LV hypertrophy impairs LV diastolic function in essential hypertension (25 -29) . In the present study, the deterioration of LV diastolic function was shown to be induced by the concentric change in LV geometry (the increase in RWT), independent of age, sex, obesity, and blood pressure. In a previous study that investigated the relation of the LV geometric pattern to LV diastolic function, the LV diastolic function of hypertensive subjects, as evaluated by the E/A ratio, was most decreased in the concentric hypertrophy group (30) . Furthermore, Pearson et al. (31) showed that, in elderly patients with isolated systolic hypertension, there was no relation between LVMI and any Doppler variable of LV filling, but there was a significant relation between RWT and the A wave and the E/A ratio. Our present findings concerning the relations of LV hypertrophy and geometry to LV diastolic function are all compatible with these observations. Taken together, these results suggest that the disturbance of LV diastolic function (abnormal relaxation) in hypertensive patients is probably caused mainly by the concentric change in LV geometry rather than the simple increase in LV mass.
In the present study, no univariable correlation between PAC and IVSTd, PWTd, or LVMI was observed in patients with treated essential hypertension. These findings are in agreement with those of previous studies (9 -11) . The previous studies showed that plasma or serum aldosterone levels were not linked to any variable of LV structure in patients with untreated essential hypertension, although plasma angiotensin II concentrations were related to some of the indices of LV hypertrophy. In contrast to these and the present findings, other studies have shown a positive correlation between aldosterone levels and LVMI in patients with essential hypertension (32, 33) . The reason for the divergent findings among these studies is unclear, but it may be partly attributable to differences in the distribution of subjects with different LV geometric patterns.
Fig. 3. Correlation between plasma aldosterone concentration (PAC) and the E /A ratio in the subgroup with increased relative wall thickness (RWT) (A) and with normal RWT (B). A significant correlation between these variables was ob-
In our study, PAC was highest in patients with eccentric LV hypertrophy, and second highest in those with concentric LV remodeling. PAC in the eccentric hypertrophy group was significantly increased compared with that in the concentric hypertrophy group. Muscholl et al. (34) reported that hypertensive subjects with eccentric LV hypertrophy and LV remodeling had significantly elevated aldosterone levels compared with those with normal LV geometry and concentric LV hypertrophy. In their study, after adjustment for covariates such as blood pressure, body mass index, and age, significant associations between aldosterone and LV wall thickness were eliminated, but aldosterone remained elevated in specific patterns of LV geometry, that is, eccentric LV hypertrophy and LV remodeling. Both eccentric LV hypertrophy and LV remodeling are particular for alternations of circulating plasma volume, as their study discussed in detail. Thus, the present findings are consistent with theirs. Moreover, a previous study revealed that the hearts of patients with primary aldosteronism, which condition is characterized by primary elevation of aldosterone, have higher LVDd but lower RWT than those of patients with renovascular hypertension (35) , suggesting that the heart in hyperaldosteronism displays a geometric pattern of eccentric LV hypertrophy. Conversely, Shigematsu et al. (36) observed significantly high plasma aldosterone levels in patients with essential hypertension who had concentric LV hypertrophy. However, the concentric hypertrophy in their study was linked to increased peripheral vascular damage i.e., to hypertensive retinopathy and renal involvement in addition to the increased systolic blood pressure and plasma renin activity. It is therefore possible that renal damage and LV hypertrophy result from more-sustained hypertension, which would lead to renin-angiotensin-aldosterone system activation and a further multiplication of vascular damage. In the present subjects, on the other hand, there were no differences in serum creatinine, serum potassium, or plasma renin activity among the four groups with different LV geometries, and PAC had no direct correlation with any of these factors.
Aldosterone has both a myocardial and a renal effect that substantially affect cardiac function. Aldosterone influences cardiac load indirectly via sodium and volume retention in distal tubules and the collecting duct of the kidney, and it may induce eccentric LV hypertrophy, as mentioned previously. Regarding the direct cardiac effect, aldosterone has been shown to increase the extracellular matrix and collagen deposition in myocardium by enhancing the expression of cardiac types I and III collagen genes (37, 38) . These effects would lead to cardiac fibrosis and diastolic stiffness (15, 39) .
We have demonstrated in the present study that PAC was related to LV diastolic dysfunction in hypertensive patients who had normal RWT. In the overall subject group, no simple correlation was detected between PAC and parameters of LV inflow, whereas an evaluation by multiple regression analysis showed that PAC was one of the independent predictors for the E/A ratio. Little has been reported on the relation of aldosterone to LV diastolic function in essential hypertension (34, 40) . Fagard et al. (40) showed in 73 patients that PAC had inverse correlations with the E wave and E/A. Another study by Muscholl et al. (34) reported in 104 patients that no association was detected between PAC and diastolic LV filling velocities including the E/A ratio. Although the exact reason for such discrepant findings has not been sufficiently explained, our present results suggest that the LV geometric pattern, especially concentric hypertrophy, may be a stronger determinant of LV diastolic dysfunction than plasma aldosterone. On the other hand, our results also suggest that a greater impairment of diastolic function may occur in hypertensive patients with higher PAC when their hearts are not involved in the concentric LV geometric change.
In the present study, LV diastolic function was mainly assessed by the E/A ratio. As a limitation of this study, however, it must be recognized that LV diastolic filling patterns determined by Doppler echocardiographic measurements permit only an indirect estimate of LV diastolic function. In addition, LV filling is influenced by a variety of factors, such as ventricular relaxation, myocardial stiffness, coronary blood flow, preload, afterload, atrial function, and heart rate. Furthermore, its pattern is considerably altered by aging, as observed in this study (Table 4) . However, our study also revealed that both RWT and PAC were associated with the E/A ratio, independent of age.
The majority of patients in the present study had received antihypertensive drugs in our hospital. Since some types of antihypertensive agents affect the production of aldosterone independent of blood pressure, we also analyzed the effect of each antihypertensive treatment on PAC. However, no type of medication affected PAC in the present patients. The rate of subjects treated with an ACE inhibitor was higher in patients with concentric hypertrophy and with eccentric hypertrophy than in those with normal geometry, but the rate did not differ between the two hypertrophic groups. These findings suggest that the observed increase in PAC in patients with eccentric LV hypertrophy was not likely to have been due to modifications associated with ACE inhibitor treatment. However, we cannot completely exclude the possibili-ty that antihypertensive treatments may have affected the cardiac structure and function, since we could not analyze the difference for each antihypertensive treatment due to the small sample size.
In patients with hypertension or congestive heart failure, continuous ACE inhibitor therapy does not necessarily produce a significant decrease in circulating aldosterone levels, which may remain high or eventually increase during longterm use (41, 42) . Although the exact mechanism by which aldosterone production may "escape" despite the ACE inhibition remains to be determined, angiotensin II is known to be synthesized via a non-ACE-dependent pathway as well as by ACE-dependent mechanisms. In addition, aldosterone may be produced by non-angiotensin II-dependent mechanisms involving adrenocorticotropic hormone, potassium, and other unknown stimulators (12, 43) . Therefore, even if the production and actions of angiotensin II are largely controlled by ACE inhibitors and angiotensin II receptor blockers, these drugs would not suppress aldosterone-specific effects. Since the present study indicated that PAC was related to specific changes in LV geometry and to LV diastolic dysfunction, aldosterone escape during ACE inhibitor therapy may have some harmful effects on cardiac structure and function. Indeed, a recent study demonstrated that the blockade of aldosterone receptors by spironolactone markedly reduced the risk of both morbidity and mortality among patients with severe heart failure who were being treated with an ACE inhibitor (44) . Sato et al. (14) also showed that spironolactone elicited beneficial effects on LV hypertrophy in patients with essential hypertension who were receiving an ACE inhibitor. On the basis of these findings and the present observations, it appears to be important to block aldosterone-induced effects on the heart even in hypertensive patients treated with antihypertensive medication.
In conclusion, our observations indicate that PAC is associated with the eccentric change in LV geometry in patients with treated essential hypertension and suggest that PAC is also associated with the impaired diastolic function of LV without concentric geometric adaptations. Further investigations are necessary to evaluate whether a blockade of various actions of aldosterone improves LV geometric change and diastolic function in treated hypertension.
